Pyxis Oncology is engaged in the development of therapeutics to treat cancers. Co. develops its product candidates to kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Co. has developed a portfolio of antibody drug conjugate product candidates and monoclonal antibody (mAb) preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. Co.'s product candidates, PYX-201 and PYX-202 are in IND-enabling studies. In addition, PYX-203 is in preclinical development and it has additional preclinical mAb discovery programs. The PYXS average annual return since 2021 is shown above.
The Average Annual Return on the PYXS average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PYXS average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PYXS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|